BIOMAT Database Logo BIOMAT Database Logo

[Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. 1988

K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Japanese Foundation for Cancer Research, Division of Clinical Chemotherapy, Tokyo.

Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy). The therapy was repeated every 3 weeks until progression or until a cumulative dose of 700 mg/m2 for epirubicin. Of 25 evaluable patients, there were one with complete response (CR), 11 with partial response (PR), 10 with no change and 3 with progressive disease (PD). The overall response rate (CR + PR) was 48%, and the median duration of response was 47 weeks. The median survival time was 78 weeks for responders and 60 weeks for non-responders, and the difference was statistically significant (p = 0.02). Leukopenia, alopecia, nausea and vomiting were commonly observed, but these side effects were better tolerated than those accompanying ACF therapy. As for cardiotoxicity, there were no acute abnormal E.C.G. changes and no congestive heart failure occurred. The median cumulative dose of Epirubicin was 510 mg/m2. These results indicate that ECF therapy is as effective as ACF therapy for metastatic breast cancer with considerably better tolerability.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
June 2002, American journal of clinical oncology,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
April 2010, Anti-cancer drugs,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer.
October 1995, Australian and New Zealand journal of medicine,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Phase II study of combination vincristine, epirubicin and cyclophosphamide in advanced breast cancer in Chinese patients.
January 1991, European journal of cancer (Oxford, England : 1990),
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Weekly first-line chemotherapy of metastatic breast cancer with cyclophosphamide and epirubicin.
October 1992, Tumori,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
January 1988, Journal of cancer research and clinical oncology,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
October 2004, British journal of cancer,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
August 2012, Cancer chemotherapy and pharmacology,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study.
December 1988, Onkologie,
K Shinagawa, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and N Mizunuma
Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study.
January 1996, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!